US 12,478,666 B2
Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection
Eric J. Arts, Ontario (CA); and Jamie Mann, Ontario (CA)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed on Mar. 7, 2023, as Appl. No. 18/118,587.
Application 18/118,587 is a continuation of application No. 17/115,355, filed on Dec. 8, 2020, granted, now 11,596,682.
Application 17/115,355 is a continuation of application No. 16/252,108, filed on Jan. 18, 2019, granted, now 10,857,223, issued on Dec. 8, 2020.
Application 16/252,108 is a continuation in part of application No. 15/589,283, filed on May 8, 2017, granted, now 10,272,134, issued on Apr. 30, 2019.
Application 15/589,283 is a continuation of application No. 14/735,662, filed on Jun. 10, 2015, granted, now 9,642,890, issued on May 9, 2017.
Claims priority of provisional application 62/010,176, filed on Jun. 10, 2014.
Prior Publication US 2023/0390377 A1, Dec. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61P 31/18 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 39/39 (2013.01); A61P 31/18 (2018.01); A61K 2039/572 (2013.01); A61K 2039/6075 (2013.01); A61K 45/06 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16134 (2013.01)] 20 Claims
 
1. A composition for reducing a latent HIV-specific memory CD4+ T cell pool in a subject, the composition comprising:
heterogenous virus-like particles (VLPs) and a pharmaceutically acceptable carrier, wherein the heterogenous VLPs comprise heterogenous near full length (NFL) HIV-1 backbone proteomes, wherein the heterogenous proteomes include at least one env, gag, or pol coded HIV-1 protein sequence
derived from heterogenous allogenic infecting HIV-1 viruses, and wherein heterogenous VLPs stimulate latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.